IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited’s subsidiary, Imaging Biometrics, has received a second Rare Pediatric Disease Designation from the U.S. FDA for its lead drug candidate, IB-003, for treating pediatric-type diffuse High Grade Glioma (HGG). The designation, which follows previous approvals and a promising pre-clinical study showing significant survival benefits, potentially offers strategic and financial incentives, including priority review vouchers for future treatments. IQ-AI is focused on accelerating and broadening the use of IB-003 to improve outcomes for children with these life-threatening conditions.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
